EMERYVILLE, Calif. and OSS, Netherlands, June 29 /PRNewswire/ -- KineMed, Inc., a pathway-based drug discovery and development company, and Organon announced today that they have signed an agreement to discover new applications for multiple drug candidates.
Under the terms of the agreement, KineMed will apply its proprietary technologies (AquaTag(TM) and KineMarker(TM)) to find alternative applications for discontinued compounds formerly in Organon’s clinical-stage pipeline. Once therapeutic utility is established for a selected drug candidate, KineMed and Organon will jointly determine a development and commercialization path, including a potential joint development and commercialization program.
David Nicholson, Executive Vice President of Global Research & Development at Organon, stated, “We at Organon are dedicated to maximize the potential of R&D compounds. KineMed’s ability to measure the outputs of complex pathways in in vivo studies may lead to the discovery of new indications and as such holds great promise.”
“Our focus at KineMed is to maximize the value of drug compounds, applying our technology to discover indications that would have otherwise gone undetected and thereby enabling new avenues for drug development and commercialization,” said David Fineman, President and CEO of KineMed. “We are pleased to announce the collaboration with Organon, which is a significant demonstration of our ability to forge partnerships with healthcare organizations that are leading the innovation of new therapies worldwide.”
About KineMed, Inc.
KineMed, Inc. is a pathway-based drug discovery and development company employing its proprietary biomarker technology (AquaTag(TM) and KineMarker(TM)) to measure the real-time activity of drugs in whole body systems. KineMed is developing therapeutics both on its own and with pharma collaborators, efficiently translating compounds into drugs with a desired biological effect on validated disease pathways. KineMed’s technology expedites the drug development process and has demonstrated results in metabolic disorders, neurodegeneration, diseases of inflammation and cancer, among other conditions. For further information about KineMed, please visit: http://www.kinemed.com
About Organon
Organon -- with shared head offices in Roseland, NJ, USA and Oss, The Netherlands -- creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading biopharmaceutical companies in each of its core therapeutic fields: fertility, gynecology, anesthesia and neuroscience. Research areas also include immunology and oncology. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.
Safe Harbor Statement*
This report contains statements which address such key issues as Organon’s growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the “Outlook,” should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more complete discussion of the risk factors affecting our business please see the Akzo Nobel Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company’s website http://www.akzonobel.com .
* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
KineMed, Inc.
CONTACT: Brent Vaughan, Chief Business Officer of KineMed, Inc.,+1-510-655-6525, ext. 110; or Media: Justin Jackson of Burns McClellan,jjackson@burnsmc.com, or Investors: John Cummings, jcummings@burnsmc.com,both of Burns McClellan, +1-212-213-0006, both for KineMed, Inc.; MoniqueMols, Director Media Relations, Organon, monique.mols@organon.com,+31-412-66-54-40
Web site: http://www.kinemed.com/
